InflaRx Unveils Promising Preclinical Findings for INF904

InflaRx Showcases New Developments for INF904

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company known for its innovative anti-inflammatory therapeutics that target the complement system, recently revealed exciting preclinical findings for its oral C5aR inhibitor, INF904. This announcement was made during the 2024 European Meeting on Complement in Human Diseases (EMCHD) held in Lübeck, Germany, where industry experts gathered to discuss advancements in the field of inflammation.

Leadership Engagement at EMCHD

Members of InflaRx's leadership team actively participated in a satellite symposium, addressing the critical role of the C5a/C5aR1 axis in inflammation. They also contributed to discussions on the importance of targeting C3 and C5 as part of inflammation treatment strategies. Additionally, the company hosted a lunch seminar that provided insights into C5a/C5aR inhibition and its potential applications in human diseases.

Insights from the Chief Medical Officer

Dr. Camilla Chong, Chief Medical Officer of InflaRx, expressed enthusiasm about the preclinical data presented at EMCHD 2024. She stated, “We welcome the opportunity to demonstrate our commitment to advancing the science of complement inhibition. The findings emphasize our goal of developing leading anti-inflammatory therapies through C5a and C5aR inhibition.” This preclinical evidence highlights INF904's significant anti-inflammatory capabilities and robust pharmacokinetic properties.

Understanding INF904's Mechanism

Within the study, INF904 was characterized as a highly selective and potent inhibitor of C5aR1, displaying impressive pharmacokinetic (PK) attributes. In controlled tests, INF904 exhibited a 96.5% inhibition of C5a-induced neutropenia, outperforming avacopan, which achieved a 51.1% inhibition at the same dosage. Furthermore, INF904's PK profile was notably superior, revealing 2- to 5-fold higher drug exposure across various animal models compared to avacopan, indicating a promising therapeutic outlook.

Pharmacological Characterization of INF904

The findings further demonstrated that INF904 has a much weaker inhibition of CYP3A4/5 enzymes, crucial for metabolizing many medications, such as glucocorticoids. This property suggests that INF904 may offer a safer alternative in terms of drug interactions, which is particularly significant for patients requiring multiple therapies.

Potential of INF904 in Inflammatory Diseases

INF904 is not only a groundbreaking C5a receptor antagonist but also shows promising effects in various inflammatory disease models. The results from in vitro and in vivo assessments reveal that INF904 effectively reduces neutrophil activation, a key contributor to inflammation. In both whole blood disease models and hamster models, the compound successfully decreased neutrophil influx and improved relevant biochemical indicators, showcasing its potential in therapeutic applications.

Therapeutic Effects Demonstrated

In clinical observations, INF904 has shown significant improvements in metabolic markers such as CREA and BUN levels. These therapeutic effects highlight the extensive potential of INF904 as an anti-inflammatory treatment, aligning with ongoing efforts to develop advanced therapies for conditions driven by excessive inflammation.

About InflaRx: A Commitment to Innovation

Founded in 2007, InflaRx is dedicated to discovering and developing potent anti-inflammatory agents by leveraging its proprietary technologies. Its lead product candidate, vilobelimab, has already demonstrated clinical efficacy and has gained attention in various studies. InflaRx continues to forge ahead with its research initiatives, including further development of INF904, which is positioned as a pioneering oral treatment option.

Contact Information

For further inquiries, reach out to InflaRx N.V. or its partner MC Services AG via the following:

InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de

MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752

Frequently Asked Questions

What is INF904?

INF904 is an orally administered small molecule that acts as a C5a receptor antagonist, showing promise in reducing inflammation.

How was INF904 evaluated?

INF904's effects were assessed through various preclinical models, including in vivo assessments and cell-based assays.

What sets INF904 apart from other treatments?

Its selective inhibition of C5aR1 and minimal impact on crucial metabolic enzymes such as CYP3A4/5 suggest lower potential for drug interactions.

What are the anticipated benefits of INF904?

The findings indicate strong anti-inflammatory effects, particularly in neutrophil-driven inflammatory responses, making it a hopeful candidate for further clinical exploration.

How does InflaRx plan to progress with INF904?

InflaRx is committed to advancing INF904 through continued research and development, aiming for clinical applications in inflammatory diseases.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.